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Summary
Mitochondria are the powerhouse of the cell and their disruption leads to cell death. We have used a peptide trivalent
arsenical, 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO), to inactivate the adenine nucleotide translocator
(ANT) that exchanges matrix ATP for cytosolic ADP across the inner mitochondrial membrane and is the key component
of the mitochondrial permeability transition pore (MPTP). GSAO triggered Ca2-dependent MPTP opening by crosslinking
Cys160 and Cys257 of ANT. GSAO treatment caused a concentration-dependent increase in superoxide levels, ATP depletion,
mitochondrial depolarization, and apoptosis in proliferating, but not growth-quiescent, endothelial cells. Endothelial cell
proliferation drives new blood vessel formation, or angiogenesis. GSAO inhibited angiogenesis in the chick chorioallantoic
membrane and in solid tumors in mice. Consequently, GSAO inhibited tumor growth in mice with no apparent toxicity at
efficacious doses.
Introduction The adenine nucleotide translocator (ANT) is a 30 kDa pro-
tein that spans the inner mitochondrial membrane and is central
Mitochondria are the focal point for a variety of proapoptotic to the MPTP (LeQuoc and LeQuoc, 1988; Halestrap et al., 1997).
signals and play a key role in the control and execution of Other mitochondrial proteins, including cyclophilin D, the volt-
the apoptotic program (Green and Evan, 2002). Proapoptotic age-dependent anion channel, the peripheral benzodiazepin re-
stimuli, mitochondrial Ca2 overload, and oxidative stress pro- ceptor, and Bcl-2 family members interact with ANT and influ-
mote the opening of a nonspecific pore that spans the inner and ence the MPTP (Crompton, 1999; Halestrap et al., 2002). Thiol
outer mitochondrial membranes, known as the mitochondrial oxidizing or alkylating agents are powerful activators of the
permeability transition pore (MPTP) (Haworth and Hunter, 1979; mitochondrial permeability transition that act by modifying one
Hunter and Haworth, 1979; Crompton, 1999; Halestrap et al., or more of the three unpaired cysteines in the matrix side of
2002). Opening of the MPTP is accompanied by equilibration ANT (Halestrap et al., 2002). For this reason, the small trivalent
of all small solutes (1.5 kDa) across the inner mitochondrial arsenical, phenylarsenoxide (PAO), is a potent activator of the
membrane, leading to mitochondrial swelling and outer mem- pore (Lenartowicz et al., 1991; McStay et al., 2002). Inorganic
brane rupture, collapse of the proton motive force, uncoupling arsenic also activates the pore (Larochette et al., 1999; Belzacq
of oxidative phosphorylation, and hydrolysis of ATP produced et al., 2001).
by glycolysis. Transient MPTP opening results in the release PAO reacts with two thiols in ANT (McStay et al., 2002)
of cytochrome c and the apoptosis-inducing factor from the forming a stable cyclic dithioarsinite in which both sulfur atoms
mitochondrial intermembrane space, which in turn activates the are complexed to arsenic (Adams et al., 1990). Trivalent arseni-
caspase cascade (Crompton, 1999). A physiological role for cals are selective for closely spaced dithiols, as the ring struc-
the MPTP in rapid dissipation of mitochondrial Ca2 overload tures formed between trivalent arsenicals and dithiols are mark-
edly more stable than the noncyclic products formed withhas also been suggested (Rizzuto et al., 2000).
S I G N I F I C A N C E
This study describes a way of selectively inactivating mitochondria in proliferating endothelial cells both in vitro and in vivo. Specifically,
mitochondria in angiogenic endothelial cells in tumors have been targeted, which resulted in inhibition of tumor angiogenesis and
tumor growth. This has been achieved using a peptide trivalent arsenical that inactivates a key mitochondrial transport protein (the
adenine nucleotide translocator), which leads to proliferation arrest and cell death. The rational targeting of a mitochondrial protein
with a small synthetic molecule described herein points the way to future rational design of angiogenesis inhibitors and general
anticancer agents that target proliferating cells by disrupting mitochondrial function.
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Figure 1. Structures of GSAO and GSAA
monothiols. PAO is lipophilic and is generally toxic for all cul- GSAO-mediated swelling of mitochondria decreased with in-
creasing Ca2 concentration (Figure 2B).tured cells after exposure to nanomolar concentrations for 1 day
(unpublished observations). We made a hydrophilic derivative of
PAO by attaching it to the cysteine thiol of reduced glutathione GSAO interacted directly with ANT
Considering that GSAO has the same dithiol reactivity as PAO,(GlyCysGlu) to produce 4-(N-(S-glutathionylacetyl)amino)phe-
nylarsenoxide (GSAO) (Donoghue et al., 2000) (Figure 1). We it was expected to mimic PAO’s binding to ANT. Direct interac-
tion of ANT with a biotin-tagged GSAO (4-(N-(S-(N-(6-((6-((bio-now describe the induction of mitochondrial permeability by
GSAO. The compound was toxic to proliferating, but not growth- tinoyl)amino)hexanoyl)amino)hexanoyl)-glutathionyl)acetyl)amino)
phenylarsenoxide, GSAO-B) is shown in Figures 2C and 2D.quiescent, endothelial cells in vitro and an inhibitor of angiogen-
esis in vivo. Isolated mitochondria were incubated with 10 M biotin-
tagged GSAO (GSAO-B) or GSAA (GSAA-B), the labeled pro-
teins were collected on avidin-coated beads, and the specificallyResults
bound proteins were eluted from the beads with an excess of
the small synthetic dithiol, dithiothreitol. From comparison withGSAO induced the mitochondrial permeability transition
GSAO triggered swelling of isolated rat liver mitochondria in a the control experiment using GSAA-B, four GSAO-interacting
proteins were clearly identified (Figure 2C). These proteins havetime- and concentration-dependent manner (Figure 2Ai). The
trivalent arsenical moiety of GSAO was responsible for this activ- molecular masses of 60, 32, 30, and 19 kDa. The 30 kDa
protein corresponded to ANT by Western blot (Figure 2D). Eo-ity as the corresponding pentavalent arsenical (4-(N-((S-glutathi-
onyl)acetyl)amino)benzenearsonic acid, GSAA) (Figure 1) had sine-maleimide alkylates Cys160 in ANT and blocks ADP binding
(Halestrap et al., 1997; Majima et al., 1998; McStay et al., 2002).little effect on swelling (Figure 2Aii). Positive controls for pore
opening were Ca2 and phosphate (Pi) ions (Figure 2Ai) and GSAO competed for eosine-maleimide alkylation of ANT Cys160
(Figure 2E), which implied that GSAO, like PAO, crosslinks Cys160PAO (Figure 2Aii).
ANT pore formation is controlled by the binding of Ca2, and Cys257.
cyclophilin D, and adenine nucleotides under physiological con-
ditions. The primary trigger for opening of the MPTP is a rise in GSAO localized to endothelial cell mitochondria
A striking feature of GSAO was that it rapidly localized to mito-matrix Ca2 concentration. Chelation of Ca2 with EGTA blocks
pore opening, as does an excess of other divalent metal ions chondria in viable bovine aortic (BAE) (Figure 3) and human
dermal microvascular (HMEC-1) (data not shown) endothelialsuch as Mg2 (Haworth and Hunter, 1979; Hunter and Haworth,
1979; Bernardi et al., 1992). Both EGTA and Mg2 blocked cells. GSAO was conjugated to fluorescein (GSAO-F) and its
subcellular localization was determined by confocal fluores-GSAO-dependent swelling (Figure 2Aiii). Binding of cyclophilin
D to ANT is necessary for pore opening at submillimolar Ca2 cence microscopy. Mitochondrial staining was confirmed by
colocalization of GSAO-F with the red-fluorescent Mitotrackerconcentrations. Cyclosporin A (CsA) blocks pore opening by
binding to cyclophilin D and displacing it from ANT (Crompton probe, which accumulates in the mitochondria of actively respir-
ing cells (Figure 3ii, 3iv, and 3vi) (Poot et al., 1996). The mito-et al., 1988; Halestrap et al., 2002). In addition, ADP and bon-
krekic acid (BKA) inhibit pore opening by binding to ANT and chondrial accumulation of GSAO-F was specific for the dithiol
reactivity of GSAO as it was abolished in the presence of adecreasing the sensitivity of the trigger site to Ca2 (Haworth
and Hunter, 1979, 2000; Hunter and Haworth, 1979; LeQuoc 5-fold molar excess of dimercaptopropanol (Figure 3iii), and the
corresponding pentavalent arsenical GSAA-F did not stain theand LeQuoc, 1988; Halestrap et al., 1997). CsA, ADP, and BKA
all blocked the effect of GSAO on pore opening (Figure 2Aiii). cells (Figure 3v).
Endothelial cells were incubated with 3 M tritiated GSAOThere is one cysteine in each of the three loops of ANT that
protrude into the matrix, Cys57, Cys160, and Cys257. The evidence or GSAA for 1, 2, or 3 days and the fmol of tritiated compound
per cell was determined. The rate of uptake of GSAO was linearindicates that PAO crosslinks Cys160 and Cys257 and enhances
cyclophilin D binding while antagonizing ADP binding (McStay over the 3 days (p  0.05) at 0.46  0.02 fmol·cell1·day1,
while for GSAA it was 0.35 0.02 fmol·cell1·day1. The oxida-et al., 2002). The two effects together greatly sensitize the trigger
site to Ca2 concentration, which facilitates pore opening. In tion state of the arsenical moiety, therefore, had little effect on
the rate of entry of the compound into endothelial cells. Thisaccordance with this mechanism, the time for half-maximal
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Figure 2. GSAO triggered MTP opening by bind-
ing to ANT
A: Mitochondrial swelling as measured by de-
crease in light scattering at 520 nm over 60 min.
The traces are representative of a minimum of
three experiments on at least two different mito-
chondrial preparations. Part (i): mitochondria
were incubated with nil (), 25 (), 50 (), 100
(), or 200 () M GSAO, or 150 M Ca2 and
6 mM Pi (). Part (ii): nil (), 100 M GSAA (),
100 M GSAO (), or 25 M PAO (). Part (iii):
mitochondria were incubated with 100 M
GSAO in the absence () or presence of 3 mM
Mg2 (), 100 M EGTA (), 10 M BKA (), 5
M CsA (), or 8 mM ADP (). No treatment ()
shown for comparison.
B: Mitochondria were incubated with 50 (), 75
(), 100 (), or 200 M () GSAO at increasing
Ca2 concentrations and the time for half-maxi-
mal swelling was measured.
C: Mitochondria were incubated with 10 M bio-
tin-tagged GSAO or GSAA, the labeled proteins
were collected on avidin-coated beads, and
the specifically bound proteins were eluted from
the beads with an excess of dithiothreitol. From
comparison with the control experiment using
GSAA-biotin (lane 2), four GSAO interacting pro-
teins were identified with molecular masses of
60, 32, 30, and 19 kDa (lane 1).
D: Western blot for ANT on mitochondrial proteins
that bound to GSAO-B in the absence (lane 1)
or presence (lane 2) of a 5-fold molar excess of
2,3-dimercaptopropanol (DMP).
E: SDS-PAGE of eosin-5-maleimide labeled ANT
in the absence (lane 1) or presence (lane 2) of
GSAO.
finding indicated that GSAA is a valid control compound for the induced mitochondrial swelling. The Ca2 content of BAE cells
incubated with 10% (proliferating) or 0.25% (growth-quiescent)intracellular effects of GSAO.
serum and the effect of GSAO on the viability of these cells
were measured.GSAO triggered mitochondrial depolarization
and apoptosis in proliferating, but not Relative cellular Ca2 concentrations were calculated with
the ratiometric Ca2 indicator dye Indo-1 and flow cytometry.growth-quiescent, endothelial cells
The finding that GSAO concentrated in the mitochondria of The fluorescence ratio for Ca2 bound to unbound Indo-1 was
48% higher in cells cultured for 48 hr in 10% serum comparedviable cells suggested that it might perturb mitochondrial func-
tion and cell viability. Mitochondrial Ca2 uptake has been to 0.25% serum and 22% higher in cells cultured for 24 hr. The
Ca2 content of proliferating endothelial cells was, therefore,shown to occur concurrently with increases in cytosolic Ca2
in response to physiological stimulants such as growth factors significantly higher than in quiescent cells.
BAE cells were incubated for 48 hr in the presence of GSAO,and G protein-coupled receptor agonists that are present in
serum (Hoek et al., 1995; Crompton, 1999; Rizzuto et al., 2000). and the number of cells remaining attached at the end of the
treatment was measured. The IC50 for reduction in viability ofWe anticipated, therefore, that proliferating (serum-stimulated)
cells would be sensitized to GSAO-mediated MPTP opening proliferating BAE cells after 48 hr exposure to GSAO was 75
M (Figure 4Ai), whereas the compound had little effect oncompared to growth-quiescent (nonstimulated) cells because
of the sharp dependence on Ca2 for GSAO’s effects on mito- growth-quiescent cells. The same results were observed with
HMEC-1 cells (data not shown). GSAA had no significant effectchondrial function (see Figure 2B). This would result in the selec-
tive induction of apoptosis in proliferating, but not growth-quies- on cell number at concentrations up to 1.0 mM (data not shown).
The effect of GSAO on proliferating cell viability was time depen-cent, cells. This theory was supported by the findings of Hoek
et al. (1995), who observed that elevation of cytosolic Ca2 leads dent and a function of the cell density. The IC50 for GSAO de-
creased from 75 M to 25 M when the incubation timeto Ca2 accumulation in mitochondria and an increase in PAO-
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GSAO concentration, indicating induction of apoptosis by
GSAO.
GSAO inhibited ATP production and increased superoxide
levels in proliferating, but not growth-quiescent,
endothelial cells
The binding of GSAO to ANT and induction of apoptosis was
expected to affect cellular ATP levels. The ATP content of prolif-
erating BAE cells was approximately twice that of growth-quies-
cent cells, and incubation with 150 M GSAO for 24 hr reduced
ATP levels in proliferating cells by 30% (Figure 5Ai). To confirm
that the decreased cellular ATP was due to an effect of GSAO
on mitochondrial ATP synthesis rather than mitochondrial bio-
genesis, we measured mitochondrial mass using nonyl acridine
orange. This dye binds to cardiolipin in the mitochondrial mem-
brane (Petit et al., 1992). The mitochondrial mass of proliferating
cells was approximately twice that of growth-quiescent cells
and was unchanged by GSAO treatment (Figure 5Aii).
Reactive oxygen species, such as superoxide anion (O2)
and hydrogen peroxide (H2O2), are generated as a byproduct
of respiration and play an important role as signaling intermedi-
ates in cellular proliferation, but at elevated concentrations, they
arrest proliferation and induce apoptosis by damaging many
cellular components (Raha and Robinson, 2000; Zanetti et al.,
2001). One to two percent of oxygen consumed by mitochon-
drial respiration forms O2 through leakage of respiratory chain
electrons directly to O2 (Boveris et al., 1972; Turrens and Boveris,
1980). This leakage can derive from the NADH dehydrogenase
(complex I), the succinate quinone dehydrogenase (complex II),
or the cytochrome b-c1 reductase (complex III) of the respiratory
chain (Papa, 1996; Turrens and Boveris, 1980; Raha and Rob-
inson, 2000). Elevated O2 is also an indicator of mitochondrialFigure 3. GSAO concentrated in mitochondria of viable cells
damage or dysfunction (Fantin et al., 2002; Hiura et al., 2000).
Confocal microscopy of BAE cells incubated with GSAO-F (i) and Mito-
O2 is converted in the mitochondria to H2O2 by Mn superoxidetracker Red (ii) showing colocalization of the compounds in the mitochon-
dismutase (SOD), but can also be released from mitochondriadria of a single cell. GSAO-F did not stain cells when incubated together
with DMP (iii and iv). The pentavalent arsenical, GSAA-F, also did not stain through anion channels, where it is dismuted to H2O2 by cyto-
cells (v and vi). solic Cu/Zn SOD (Vanden Hoek et al., 1998).
BAE cells were treated for 24 hr with GSAO, and the cellular
levels of O2 and H2O2 were measured using the dyes dihydro-
ethidium and CM-H2-DCFDA, respectively. Cellular levels of O2
increased from 48 hr to 72 hr. The IC50 also decreased with increased linearly with GSAO concentration in proliferating, but
decreasing cell density. PAO, in contrast, was equally toxic to not growth-quiescent, BAE cells (Figure 5B). Simultaneous anal-
both proliferating and growth-quiescent BAE cells with an IC50 ysis of cellular O2 and H2O2 levels using two channel flow
of 0.2 M (Figure 4Aii). cytometry indicated that this effect of GSAO was not due to an
Interestingly, there was a biphasic effect of PAO on endothe- inhibition of SOD activity. O2 levels were increased in the major-
lial cell viability. Low concentrations of PAO, but not GSAO, ity of cells without a corresponding decrease in H2O2 (Figure
stimulated endothelial cell proliferation. Inorganic arsenic (arse- 5C). There was no effect of GSAA on O2 or H2O2 levels (data not
nic trioxide) also has this effect on cell proliferation (Barchowsky shown). The linear increase in O2 levels with GSAO treatment
et al., 1999). The glutathione pendant of GSAO, therefore, has is consistent with a disruption of mitochondrial integrity. The
changed the properties of the trivalent arsenical. elevated O2 likely contributes directly to the proliferation arrest
GSAO treatment induced caspase-3/7 activation (Figure and induction of apoptosis.
4B), loss of mitochondrial transmembrane potential, and surface
presentation of phosphatidylserine (Figure 4C) in BAE cells. GSAO was selectively toxic towards endothelial cells
Mitochondrial transmembrane potential and phosphatidylserine compared to tumor cells
exposure were measured using the JC-1 dye and FITC-conju- To distinguish between the antiproliferative and proapoptotic
gated annexin V, respectively. The ratio of distribution of JC-1 effects of GSAO, treated cells were stained with propidium io-
between the cytosol (green fluorescence) and mitochondria (red dide (PI) to detect late-apoptotic or dead cells. The total number
fluorescence) reflects mitochondrial transmembrane potential of cells and the proportion of cells that were PI positive following
(Smiley et al., 1991). Caspase activation was commensurate 48 hr treatment with GSAO were measured by flow cytometry.
with disruption of mitochondrial potential and exposure of phos- The IC50 for proliferation arrest of BAE (Figure 6A) or primary
human dermal microvascular endothelial (Figure 6B) cells wasphatidylserine. All three parameters increased with increasing
500 CANCER CELL : MAY 2003
A R T I C L E
Figure 4. GSAO triggered mitochondrial depo-
larization and apoptosis in proliferating, but not
growth-quiescent, endothelial cells
A: Number of attached BAE cells remaining after
48 hr incubation in medium containing 0.25% or
10% serum, with GSAO (i) or PAO (ii). Results are
mean  SEM of three experiments.
B: Activation of caspases 3/7 in BAE cells follow-
ing 24 hr incubation with GSAO. Results are
mean  SEM of three experiments.
C: The percentage of cells positive for mitochon-
drial membrane depolarization (cytosolic JC-1)
and annexin V binding following 24 hr incubation
with GSAO. The same result was observed in two
different experiments.
10 M and 15 M, respectively. The IC50 for loss of viability (Nguyen et al., 1994). GSAO inhibited CAM angiogenesis (Figure
7A) in a concentration-dependent manner (Figure 7B). GSAAwas 75 M and 35 M, respectively, indicating that GSAO
arrested proliferation at lower concentrations than were neces- up to 50 g per pellet had no effect on CAM angiogenesis.
GSAO induces proliferation arrest in endothelial cells at 2.3-sary to induce apoptosis. The IC50 for proliferation arrest of
bovine vascular smooth muscle cells was 30 M. In contrast, to 7.5-fold lower concentrations than are required to trigger
apoptosis (see Figures 5A and 5B and Table 1). In the CAMall tumor cells tested were more resistant to GSAO (Figures
6C–6G). The concentrations of GSAO that induce proliferation assay, therefore, new blood vessels would not be expected to
sprout from existing vessels in the vicinity of the GSAO pellet,arrest and loss of viability are 3- to 32-fold and 2- to 9-fold
higher, respectively, for tumor cells than for endothelial cells which is what was observed. We next tested whether GSAO
would inhibit tumor angiogenesis and tumor growth in mice.(Table 1). GSAO treatment caused Lewis lung carcinoma cells
to disaggregate, which was the reason for the apparent increase
in cell number for this tumor line (Figure 6E). GSAO inhibited tumor angiogenesis and tumor growth
Mice were administered GSAO by subcutaneous injection, and
the plasma concentration of arsenic was measured by induc-GSAO inhibited CAM angiogenesis
The ability of GSAO to selectively kill proliferating, but not tively coupled plasma mass spectrometry. This should reflect
GSAO levels, as the concentration of arsenic in the plasma ofgrowth-quiescent, endothelial cells in vitro suggested that it
might be an effective inhibitor of angiogenesis in vivo. The untreated mice was below the level of detection. Subcutaneous
administration of 10 mg/kg GSAO resulted in a plasma arsenicsprouting of new capillaries from existing vessels is termed
angiogenesis and is driven by proliferating endothelial cells (Car- concentration of 6.4  0.9 M (n  5) after 30 min, which is in
the range of the IC50 for proliferation arrest of endothelial cellsmeliet and Jain, 2000). In the normal adult mammal, angiogen-
esis is confined to the female reproductive cycle, wound healing, by GSAO in culture (Table 1). Plasma arsenic peaked at 	30
min and returned to baseline after 8 hr (Figure 7C).and diseases such as rheumatoid arthritis, psoriasis, diabetic
retinopathy, and cancer. Tumor expansion and metastasis is The growth of established human and murine primary tu-
mors in immunocompromised and immunocompetent mice, re-dependent on tumor angiogenesis (Hanahan and Folkman,
1996). spectively, was suppressed by administration of GSAO. Treat-
ment of SCID mice bearing 0.1 g BxPC-3 (Figure 7D) orThe chick chorioallantoic membrane (CAM) assay has been
used for the detection and analysis of angiogenesis inhibition HT1080 (Figure 7E) tumors, or C57Bl6/J mice bearing 0.1 g
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Figure 5. GSAO inhibited ATP production and in-
creased superoxide levels in proliferating, but not
growth-quiescent, endothelial cells
A: BAE cells were cultured for 24 hr in medium
containing 0.5% or 10% serum and then for a
further 24 hr in the presence of GSAO. In part i,
cellular ATP levels were measured using a lucif-
erin/luciferase assay. Results are mean  SEM of
four experiments. In part ii, mitochondrial mass
was measured from uptake of nonyl acridine or-
ange (NAO). Results are mean  range of two
experiments.
B: Superoxide level, measured with dihydroethi-
dine, in BAE cells that had been cultured for 24
hr in medium containing 0.5% or 10% serum and
then for a further 24 hr in the presence of GSAO.
Results are mean  range of two experiments.
C: Simultaneous measurement of O2 (y axis) and
H2O2 (x axis) in BAE cells cultured in medium con-
taining 10% serum and GSAO for 24 hr. Percent-
age of cells in each quadrant is shown in the
outermost corner.
LLC tumors (Figure 7F), by subcutaneous administration of 10 at 30-fold higher concentrations (Table 1), and systemic ad-
ministration of GSAO markedly reduced tumor vascularity inmg/kg/day GSAO at a site remote from the tumor resulted in
90%,70%, and45% inhibition of the rate of tumor growth, vivo but had no effect on the proliferative index of the BxPC-3
tumor cells (Figure 7H). There was a significant increase in apo-respectively. Administration of control GSAA caused 20% in-
hibition of the rate of tumor growth in all experiments when ptosis of the BxPC-3 tumor cells, which is in accordance with
inhibition of tumor angiogenesis (O’Reilly et al., 1997). The highcompared to administration of vehicle alone (data not shown).
This small inhibition of tumor growth by GSAA was perhaps rate of apoptosis balances the high proliferative rate of the tumor
cells, resulting in no net gain in tumor size (Holmgren et al.,due to enzymatic reduction of the compound to GSAO, possibly
by a liver arsenate reductase (Radabaugh and Aposhian, 2000). 1995).
There were no apparent adverse affects of administration of
either GSAO or GSAA to either SCID or C57Bl6/J mice. The Discussion
average mice weights of the GSAO and GSAA treatment groups
over the course of the experiments were not significantly differ- GSAO localized to endothelial cell mitochondria and induced
Ca2-dependent opening of the MPTP in isolated mitochondria,ent (data not shown), and there were no macroscopic differ-
ences or morphological changes apparent in the heart, lungs, directly crosslinking two cysteine residues on the matrix side
of ANT. Perturbation of mitochondrial function in cultured endo-liver, kidneys, and spleen of GSAO- or GSAA-treated mice.
Immunohistochemical analysis of the tumors from the exper- thelial cells was evidenced as an increase in the cellular levels
of O2 at subapoptotic concentrations of GSAO, and a decreaseiment described in Figure 7D indicated a significant reduction
in blood vessel density in the GSAO-treated tumors (p 0.001) in cellular ATP and loss of mitochondrial transmembrane poten-
tial at higher GSAO concentrations. High levels of reactive oxy-(Figures 7G and 7H). The proliferative indices of the GSAA-
and GSAO-treated tumors were the same, while there was a gen species can arrest proliferation and induce apoptosis by
damaging lipids, proteins, DNA, and RNA (Raha and Robinson,significant increase in the apoptotic indices of GSAO- versus
GSAA-treated tumors (p  0.05) (Figure 7H). 2000; Davis et al., 2001; Zanetti et al., 2001). In contrast, GSAO
had little effect on mitochondrial function and viability of growth-The effect of GSAO on tumor growth is consistent with
inhibition of tumor angiogenesis. GSAO arrested proliferation of quiescent endothelial cells.
Although we cannot exclude an effect of GSAO on the activ-endothelial cells in vivo but had no effect on BxPC-3 proliferation
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Figure 6. GSAO was selectively toxic towards en-
dothelial cells compared to tumor cells
Effect of GSAO on cell proliferation and viability
for two types of primary endothelial cell (A and
B) and five tumor cell lines (C–G). Four human
(BxPC-3 pancreatic, HT1080 fibrosarcoma, A549
lung, and HL60 erythroid leukaemia) and one
murine (LLC lung) carcinoma cell lines were
tested. Results are mean  SEM of three treat-
ments.
ity of other mitochondrial proteins, the mitochondrial swelling The strong selectivity of GSAO for proliferating cells was
probably a consequence of two related events: the greater pro-and cell-based assays point to ANT as the relevant target in
terms of the consequences for endothelial cell proliferation and pensity for MPTP opening due to higher mitochondrial Ca2
levels and the higher respiration rate in proliferating cells. Theviability. ANT is the most abundant protein of the inner mito-
chondrial membrane (Klingenberg and Nelson, 1994), and it elevated cellular levels of O2 most likely resulted from uncon-
trolled production and/or release from mitochondria followinghas been well established that disruption of ANT has major
consequences for mitochondrial integrity and cell survival (Hale- opening of the MPTP by GSAO. GSAO treatment did not in-
crease cellular H2O2 levels, which implied that it did not affectstrap et al., 2002). Proving that ANT is the most relevant target
for GSAO in endothelial cells using genetic approaches is prob- the thioredoxin and glutathione thiol buffering systems (Davis
et al., 2001; Gladyshev et al., 2001; Chen et al., 2002). Depletinglematic. Overexpression of ANT in mammalian cells induces
apoptosis (Bauer et al., 1999) in a manner that may be unrelated the cellular thiol buffering capacity would be expected to result
in elevated H2O2 levels (Powis and Montfort, 2001).to formation of the MPTP (Halestrap et al., 2002).
Table 1. Effect of GSAO on proliferation and viability of endothelial and tumor cells
Cell type Proliferation arrest Loss of viability
IC50, M IC50, M
BAE (bovine aortic endothelial) 10 75
HDMVE (human dermal endothelial) 15 35
BxPC-3 (human pancreatic carcinoma) 320 320
HT1080 (human fibrosarcoma) 95 130
LLC (murine lung carcinoma) NDa 140
A549 (human lung carcinoma) 80 150
HL60 (human erythroid leukaemia) 50 140
a Not determined. LLC cells aggregate in culture and GSAO treatment caused the cells to disaggregate, which compromised the estimation of total cell
number.
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Figure 7. GSAO inhibited CAM and tumor angio-
genesis
A: Photographs of CAM’s after incubation with
methylcellulose discs containing 10 g of either
GSAA (top) or GSAO (bottom) for 48 hr. The dot-
ted circle indicates the placement of the disc.
B: The number out of 5 zones positive for angio-
genesis inhibition at 5, 10, or 50 g of GSAO per
pellet. GSAA did not inhibit CAM angiogenesis
up to 50 g per pellet.
C: Plasma arsenic concentrations following sub-
cutaneous administration of 10 mg/kg GSAO to
Balb c mice. The data points are the mean 
SEM of 3–5 mice plasmas.
D–F SCID mice bearing 0.1 g BxPC-3 (D) or
HT1080 (E) tumors, or C57Bl6/J mice bearing0.1
g LLC tumors (F), were randomized into two
groups (n  4) and treated subcutaneously with
either GSAA or GSAO at 10 mg/kg/day in 0.2
ml of PBS containing 100 mM glycine. The data
points are the mean SEM of the tumor volumes.
The arrows indicate start of treatment.
G–H Histological sections of the BxPC-3 tumors
from the experiment shown in D at day 31 of
treatment with GSAA or GSAO were analyzed
for vascularity (CD31), proliferation (PCNA), and
apoptosis (TUNEL). An example of the staining
for CD31 is shown in G, and the quantitation of
blood vessel density, tumor cell proliferation, or
apoptosis is shown in H. The stars represent sig-
nificant difference from control: ** is p  0.001
while * is p  0.05.
GSAO’s accumulation in the mitochondria of viable endo- immediate-early genes (Battini et al., 1987). However, it seems
unlikely that isoform specificity accounts for the selectivity ofthelial cells was potentially driven by its interaction with ANT,
which is abundant in the inner mitochondrial membrane. Se- GSAO for proliferating cells, since the three isoforms share95%
sequence similarity and the two cysteines that react with GSAO,questration of GSAO by mitochondrial dithiols, such as those
in ANT, would drive further entropic import of GSAO into the Cys160 and Cys257, are conserved in all three. Furthermore, we
have observed no obvious difference in GSAO’s mitochondrialmatrix. This mechanism is supported by the finding that GSAA,
which has effectively the same charge and size as GSAO, did localisation in proliferating versus growth-quiescent endothelial
cells by confocal microscopy or sub-cellular fractionation (datanot accumulate in mitochondria. Similarly, retention of the Mito-
tracker CMXRos dye is thought to be due to its reaction with not shown).
The mechanism of the selectivity of GSAO for endothelialmitochondrial protein thiols via its chloromethyl moiety (Poot et
al., 1996). versus tumor cells is under investigation. Preliminary findings
suggest that the selectivity may relate to the capacity of theThree isoforms of ANT have been described in mammalian
cells, which are differentially expressed in various human tissues cell to buffer GSAO’s arsenical moiety. A major buffer appears
to be reduced glutathione, as both endothelial and tumor cells(Ku et al., 1990; Doerner et al., 1997). The ANT2 isoform is
selectively expressed in proliferating cells together with the are more susceptible to GSAO when pre-treated with the gluta-
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in portions in 0.5 M bicarbonate buffer (100 ml). The clear solution was foundthione synthesis inhibitor buthionine sulfoximine (data not
to be pH 9 and was thoroughly mixed and left overnight at room temperature.shown). A role for cellular glutathione in buffering inorganic arse-
On the following day, the solution was acidified to neutral pH with thenic, for example, is well established (Ochi, 1997; Schuliga et
dropwise addition of 32% hydrochloric acid, and the product precipitated
al., 2002). Reduced numbers of mitochondria in tumor cells from absolute ethanol (1 liter) by dropwise addition of the acidified solution
could also explain the selectivity. It has been known for some to the well-stirred alcohol. The mixture was stirred at room temperature for
time that rapidly proliferating tumor cells have fewer mitochon- 1 hr and then left for 3 hr until the precipitate had settled. The clear ethanolic
dria, lower levels of oxidative phosphorylation and elevated an- solution was decanted until 300 ml were left, and then this was swirled
and centrifuged at 2000 g for 5 min. The product 4-(N-((S-glutathionyl)acetyl)aerobic glycolytic capacity (Pedersen, 1978; Papa, 1996).
amino)benzenearsonic acid (GSAA) was washed by resuspension in freshTwo other possible mechanisms for the anti-endothelial cell
absolute ethanol and centrifuged again. The washing was repeated twoactivity of GSAO were investigated. GSAO has been used to
more times, and the final suspension was dried to a white solid, GSAA, byprobe closely spaced protein thiols on the cell surface (Do-
rotary evaporation. The GSAA was characterized by 1H-NMR (D2O, 300 MHz)noghue et al., 2000). However, prior blocking of all cell surface and 13C-NMR (D2O, 75 MHz) and has a molecular weight of 564.
thiols with the hydrophilic thiol-alkylating agents 5,5
-dithio-
bis(2-nitrobenzoic acid) or 3-(N-maleimidylpropionyl)biocytin Synthesis of GSAO
BRAA was prepared as described above and was then converted to 4-(N-had no effect on the anti-endothelial cell activity of GSAO, indi-
(bromoacetyl)amino)benzenearsonous acid (BRAO) using the method de-cating that GSAO’s effects were not due to perturbation of
scribed in Donoghue et al. (2000). The procedure for the conversion of BRAOa cell surface protein. Certain protein tyrosine phosphatases
to GSAO is a modification of that described in Donoghue et al. (2000), as(PTPases) are inactivated by trivalent arsenicals, due to the
follows. Reduced glutathione (16 g, 52 mmol) was dissolved in deoxygenated
presence of two unpaired cysteines in the active site (one of water (1 liter) under a nitrogen atmosphere (deoxygenated water was pre-
them is the catalytic cysteine) that form cyclic dithioarsinites pared by boiling followed by cooling to room temperature, all the time under
with trivalent arsenicals (Liao et al., 1991; Defilippi et al., 1995; an atmosphere of nitrogen). BRAO (25 g, 77 mmol) was suspended in the
solution, and vigorous stirring of the mixture was applied until the undis-Yuan et al., 1998). Incubation of endothelial cells with high mi-
solved BRAO had lost all tendency to float, at which point the rate of stirringcromolar concentrations of GSAO resulted in increased tyrosine
was decreased. Triethylamine (16 ml, 11.6 g, 115 mmol) was added, andphosphorylation of two proteins (focal adhesion kinase and pax-
the mixture was stirred for at least 18 hr, all the time under nitrogen. Someillin), and GSAO was found to inhibit two PTPases (PTP-PEST
colorless solid was removed by rapid vacuum filtration, and the filtrate was
and PTP-1B). Overexpression of PTP-PEST or PTP-1B in endo- concentrated to a viscous gel on a rotary evaporator. The gel was diluted
thelial cells did not blunt GSAO’s effects on viability, however, with ethanol (250 ml), the rate of stirring was increased, and then acetone
which implied that these PTPases were not GSAO’s primary (250 ml) was added, with formation of a white solid. After stirring for 2 hr
under nitrogen, the solid was collected by vacuum filtration and dried at roomtarget. Furthermore, inhibition of PTPase activity would be pre-
temperature under vacuum to a constant weight. Analysis of the material bydicted to enhance endothelial proliferation and survival (Mon-
1H-NMR allowed the amount of triethylamine to be determined. An equiva-tesano et al., 1988). In fact, a PTP-1B inhibitor has recently
lent amount of sodium hydroxide (i.e., 1 mmol NaOH per mmol triethylamine)been shown to promote neovascularization (Soeda et al., 2002).
was added in the form of a 10 M aqueous solution to a solution of the
GSAO inhibited tumor angiogenesis and tumor growth in material in the minimum amount of deoxygenated water. The solution was
mice with no apparent side effects. The safety of GSAO in mice stirred under nitrogen for 2 hr, and GSAO (as the sodium salt) was obtained
may be due to its hydrophilicity, which limits its entry into cells by removal of the solvent on a rotary evaporator. The GSAO was character-
ized by the following methods: 1H-NMR (D2O, 400 MHz), 13C-NMR (D2O, 100and confines its distribution mostly to the intravascular compart-
MHz), HPLC, and infrared spectroscopy (nujol mull). The elemental analysisment. Preliminary studies in mice have shown that GSAO is
was consistent with a composition of GSAO.2H2O, and the mass spectrumrapidly excreted in the urine within 30 min of intravenous admin-
gave the parent molecular ion at 549.1 min·u· [GSAOH]. The purity ofistration and does not appear to accumulate in any organs.
GSAO was 94% by HPLC.
Our findings indicate that hydrophilic dithiol-reactive com-
pounds like GSAO appear to be an effective means of inhibiting Synthesis of biotin and fluorescein derivatives of GSAO and GSAA
endothelial cell proliferation and angiogenesis. A key aspect of GSAO-B was produced as described by Donoghue et al. (2000) and has a
this molecule is the glutathione pendant that safely delivers the molecular weight of 1001. A solution of fluorescein-5-EX succinimidyl ester
(Molecular Probes, Eugene, Oregon) (2.4 mg, 4.1 mol) in DMSO (240 l)arsenical warhead to endothelial cell mitochondria both in vitro
was added to GSAO or GSAA (33.8 mM) in Mes buffer, pH 5.5 (5 mM, 473and in vivo. The features of this pendant that permit delivery of
l), the mixture was diluted with bicarbonate buffer, pH 9 (0.5 M, 3.287 ml)the arsenical are currently being defined and refined.
and allowed to stand at room temperature for 80 min. The reaction was then
diluted with glycine (100 mM) in phosphate-buffered saline (PBS) (4 ml) andExperimental procedures
allowed to stand at room temperature overnight. The final solution contained
trivalent arsenical (2 mM) and glycine (50 mM). The molar ratio of fluorescein-Synthesis of GSAA
5X to GSAO or GSAA was 1.5:1. The molecular weights of GSAO- andBRAA was prepared by a modification of the method described in Donoghue
GSAA-fluorescein (GSAO-F and GSAA-F) are 1024 and 1040, respectively.et al. (2000). p-Arsanilic acid (20.6 g, 95 mmol) was added in portions to a
solution of sodium carbonate (20 g, 189 mmol) in water (200 ml). When all
Assay of arsenical concentrationsolids had dissolved, the solution was found to be pH 10 and was chilled
The concentrations of GSAO, GSAO-B, and GSAO-F were measured byat 4C for 2 hr. Bromoacetyl bromide (15 ml, 173 mmol) in dry dichlorometh-
titrating with dimercaptopropanol and calculating the remaining free thiolsane (35 ml) was added in two portions, each addition followed by vigorous
with 5,5
-dithiobis(2-nitrobenzoic acid) (Sigma, St. Louis, Missouri) (Don-shaking for 2 to 3 min. The mixture was allowed to stand for a few min, and
oghue et al., 2000). The conjugates were sterile filtered and stored at 4Cthe lower organic layer was drained off. 4-(N-(Bromoacetyl)amino)benzen-
in the dark until use. There was no significant loss in the active concentrationearsonic acid (BRAA) was precipitated by acidification of the solution to
of stock solutions of the arsenicals for at least a month when stored underabout pH 2–3 with the dropwise addition of 98% sulfuric acid, collected by
these conditions. All GSAO and GSAA solutions used for experiments werevacuum filtration and dried, giving BRAA as a white solid. BRAA (3.38 g, 10
dissolved in PBS containing 100 mM glycine. The glycine slows the oxidationmmol), reduced glutathione (3.23 g, 10.5 mmol), and sodium bicarbonate
(3.15 g, 37.5 mmol) were mixed together, and the solid mixture was dissolved of GSAO to GSAA (Donoghue et al., 2000).
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Mitochondrial swelling assay Immunocytochemistry and confocal microscopy
Mitochondria were isolated from the livers of 250 g male Wistar rats using BAE cells were seeded at a density of 104 cells per well into 8-well Labtek
differential centrifugation as described previously (Schnaitman and Greena- glass chamber slides (Nunc, Naperville, Illinois) and allowed to adhere over-
walt, 1968). The final mitochondrial pellet was resuspended in 3 mM HEPES- night. The cells were then incubated for 1 hr with 50 M GSAO-F, 50 M
KOH, pH 7.0 buffer containing 213 mM mannitol, 71 mM sucrose, and GSAO-F and 250 M dimercaptopropanol, or 50 M GSAA-F. All cells
10 mM sodium succinate at a concentration of 30 mg of protein per ml. were counterstained with 100 nM MitotrackerTM Red CMXRos (Molecular
Mitochondrial permeability transition induction was assessed spectrophoto- Probes). The cells were then washed three times with serum-free medium
metrically by suspending the liver mitochondria at 0.5 mg of protein per ml and fixed for 10 min with 80% acetone and 20% methanol. Slides were
at 25C in 3 mM HEPES-KOH, pH 7.0 buffer containing 75 mM mannitol, mounted in VectaShield antifade agent (Vector Laboratories, Burlingame,
250 mM sucrose, 10 mM sodium succinate, and 2 M rotenone. Swelling California) and sealed with nail polish. Images were captured using a Leica
was measured by monitoring the associated decrease in light scattering at DM IRB inverted microscope and confocal system, with Leica confocal
520 nm using a Molecular Devices Thermomax Plus (Palo Alto, California) software.
microplate reader. All reagents were purchased from Sigma.
Cellular uptake assay
Detection of mitochondrial proteins that bind GSAO GSAO or GSAA was synthesized using tritiated glutathione (Amersham Bio-
Rat liver mitochondria were suspended at 1 mg protein per ml in 3 mM sciences, Buckinghamshire, United Kingdom). HMEC-1 cells were seeded
HEPES-KOH, pH 7.0 buffer containing 213 mM mannitol, 71 mM sucrose, at a density of 5  105 cells per well in 6-well culture plates and allowed to
and 10 mM sodium succinate and incubated with 10M GSAO-B or GSAA-B attach overnight. Cells were incubated with 3 M tritiated GSAO or GSAA
for 1 hr at room temperature on a rotating wheel. The mitochondria were in the presence of 100 M unlabeled reduced glutathione. The medium was
washed once with buffer, then sonicated in 0.3 ml ice-cold 25 mM Tris, pH removed and the cells were washed twice with PBS, detached with 20 mM
7.4 buffer containing 140 mM NaCl, 2.7 mM KCl, 0.5% Triton X-100, 0.05% EDTA/PBS, washed once with PBS, and solubilized with 100 l of 20 mM
Tween-20, 3 M Urea, 10 M leupeptin, 1 M aprotinin, 50 g.ml1 4-2- Tris, pH 7.4 buffer containing 0.14 M NaCl, 1% Triton X-100, 0.5% sodium
(aminoethyl)-benzene sulfonyl fluoride and 5 mM EDTA. Lysate was clarified deoxycholate, 0.1% SDS, 2 mM EGTA, 50 g·ml1 AEBSF, 10 g·ml1
by centrifugation at 18000 g for 10 min at 4C and incubated with 30 l of leupeptin, 1.0 M aprotinin, and 1 g·ml1 pepstatin A. Samples were mixed
streptavidin-dynabeads (Dynal, Oslo, Norway) for 2 hr at 4C to isolate the with 5 ml aqueous scintillant ACSII (Amersham Pharmacia, Uppsala, Swe-
biotin-labeled proteins. The beads were washed twice with sonication buffer den) and counted for 4 min. Results were the mean  standard error of
and twice with 25 mM Tris buffer containing 140 mM NaCl and 0.5% Triton triplicate cell treatments.
X-100. Proteins bound specifically to GSAO’s arsenical moiety were eluted
from the beads by incubation with 40 l of 25 mM Tris buffer containing 50 Cellular Ca2 assay
mM dithiothreitol for 5 min (Donoghue et al., 2000). The eluted proteins were
BAE cells were seeded at 105 cells per well into 12-well plates in medium
resolved on 8%–16% gradient iGels (Gradipore, Sydney, Australia) under
containing 10% serum, allowed to adhere overnight, then cultured for 24 or
reducing conditions and silver stained.
48 hr in medium containing 10% or 0.25% serum. The cells were washed
with PBS, incubated for 30 min in PBS containing 0.2% BSA and 2.5 M
Binding of GSAO to ANT
Indo-1 (Sigma), washed once, then incubated for 60 min in medium con-
Rat liver mitochondria were prepared as described above and incubated
taining 0.25% or 10% serum. The cells were detached with trypsin/EDTA,
with 10 M GSAO-B in the absence or presence of 50 M 2,3-dimercapto-
washed once to remove trypsin, resuspended in growth medium, and trans-
propanol (Fluka, Buchs, SG, Switzerland). The GSAO-B labeled proteins
ferred to ice. Fluorescence was measured immediately using excitation at
were collected as described above, resolved on 8%–16% gradient iGels
350 nm and 510/20 nm (Ca2 bound) and 440/40 nm (Ca2-free) emission
under reducing conditions, and transferred to PVDF membrane. Proteins
filters. The ratio of violet/blue fluorescence was used to determine the relative
were detected by Western blot using a 1:500 dilution of goat anti-human
intracellular Ca2 concentration.
ANT polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, California)
and 1:2000 dilution of rabbit anti-goat peroxidase-conjugated antibodies
Cell proliferation and viability assays(Dako, Carpinteria, California).
To assay cell number with methylene blue, BAE cells were seeded at a
density of 104 cells per well into 96-well plates and allowed to adhere over-Labeling of ANT with eosin-5-maleimide
night. Cells were arrested for 24 hr in medium containing 0.25% serum andRat liver submitochondrial particles were prepared by sonication and differ-
cultured for a further 48 hr in medium containing 0.25% or 10% serum, inential centrifugation according to Majima et al. (1998). The particles were
the presence of GSAO or PAO. Attached cells remaining after treatmentssuspended at 20 mg of protein per ml in 10 mM Tris, pH 7.2 buffer containing
were measured using methylene blue (Oliver et al., 1989). The anti-prolifera-250 mM sucrose and 0.2 mM EDTA and incubated without or with 200 nmol
tive and cytotoxic effects of GSAO were assayed by flow cytometry withGSAO per mg of protein for 10 min at 25C, followed by 20 nmol of eosin-
propidium iodide. Endothelial and tumor cells were seeded at a density of5-maleimide per mg of protein for 1 min at 0C in the dark. The labeling was
5  104 cells per well into 12-well plates, allowed to adhere overnight, thenterminated by addition of 10 mmol of dithiothreitol per mg of protein. The
treated for 48 hr with GSAO. Adherent cells were detached with trypsin/proteins were resolved on 4%–20% gradient iGels and the eosin-labeled
EDTA and combined with the growth medium containing the cells that hadANT was visualized by UV transillumination using a Fluor-S MultiImager
detached during treatment. The combined cells were pelleted, resuspended(Bio-Rad, Hercules, California).
in 0.5 ml serum-free medium containing 1 g·ml1 propidium iodide (PI)
(Molecular Probes), and analyzed by flow cytometry. The number of viableCell culture
cells in the untreated control was normalized to 100%, and viability for allBAE cells were from Cell Applications, San Diego, California and BxPC-3,
GSAO treatments was expressed as a percentage of control.HT1080, LLC, A549, and HL60 cells were from ATCC, Bethesda, Maryland.
BAE, HT1080, and LLC cells were cultured in DMEM, BxPC-3 cells in RPMI
ATP assaymedium, A549 cells in F-12K medium, HL60 cells in IMDM, and HMEC-1
BAE cells in 6-well culture plates were arrested for 24 hr in 0.5% serum orcells (Ades et al., 1992) in MCDB131 medium. The cells were supplemented
left in 10% serum, then treated for 24 hr with GSAO. The cells were washedwith 10% fetal calf serum (FBS), 2 mM L-glutamine, and 1 U·ml1 penicillin/
once then resuspended in 0.4 ml PBS containing 0.2% bovine serum albu-streptomycin. HDMVE cells were a gift from Dr. Chris Jackson (Jackson et
min. A 50 l sample of cells was mixed with 50 l water and 100 l ATPal., 1990) and cultured in MCDB131 supplemented with 20% human serum,
releasing agent and ATP concentration was measured using a luciferin/50 g·ml1 endothelial cell growth supplement, 50 g·ml1 heparin, 10
luciferase ATP assay mix (Sigma). Light units were converted to ATP concen-ng·ml1 epidermal growth factor, and 1 g·ml1 hydrocortisone. Cell culture
trations using an ATP standard in place of the 50 l water. Cell number wasplasticware was from Techno Plastic Products (Trasadingen, Switzerland).
counted using a Beckman Coulter Counter and mol of ATP was expressedEpidermal growth factor, hydrocortisone, and heparin were from Sigma. All
other cell culture reagents were from Gibco (Gaithersburg, Maryland). per million cells.
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Caspase activation assay crovessels were counted in three tumors, including the smallest and largest,
from the control and treatment groups, and the density was graded in theBAE cells were seeded at a density of 104 cells per well in a 96-well plate
and allowed to adhere overnight. The cells were incubated with increasing most active areas of neovascularization according to Weidner et al. (1991).
The proliferative index was estimated by the percentage of cells scoredconcentrations of GSAO for 24 hr and caspase-3/7 activity was determined
using the APO-ONE Homogeneous Caspase-3/7 Assay (Promega, Madi- under 400 magnification. A minimum of 1000 cells was counted in 3–5
sections. The apoptotic index was estimated by the percentage of cellsson, Wisconsin).
scored under 400 magnification. A minimum of 15000 cells was counted
in 12–15 sections.Superoxide, mitochondrial membrane potential, mitochondrial
mass, and apoptosis assays
Proliferating or growth-quiescent BAE cells were treated for 24 hr with GSAO Acknowledgments
in 6-well culture plates, then detached with trypsin/EDTA, washed once,
and resuspended at 2  106 cells per ml in serum-free medium. Cells were This study was supported by NIH grant RO1-CA64481 and grants from the
National Health and Medical Research Council of Australia, the New Southincubated for 30 min at room temperature with 0.5 g·ml1 JC-1, 50 l·ml1
annexin V-FITC, or 5 M acridine orange 10-nonyl bromide (NAC), then Wales Cancer Council, and an infrastructure grant from the NSW Health
Department. The technical assistance of Geraldine Jackson, Daniella Prox,washed once, resuspended in 0.5 ml serum-free medium, transferred to
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thank Janet Keast for providing the rat livers.measure superoxide and hydrogen peroxide, the cells were incubated for
15 min at room temperature with 5 M dihydroethidine (HE) and 5 M CM-
H2-DCFDA in 0.5 ml serum-free medium, then immediately assessed by flow
cytometry. JC-1, NAC, HE, CM-H2-DCFDA were from Molecular Probes.
Annexin V was from Pharmingen (La Jolla, California). Received: January 9, 2003
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CAM assay Published: May 19, 2003
Fertilized 3-day-old white Leghorn eggs (Spafas, Norwich, Connecticut) were
cracked, the embryos with intact yolks placed in 20  100 mm petri dishes References
and incubated for 3 days at 37C and 3% CO2 (Folkman, 1985). Methylcellu-
lose (Fisher Scientific, Fair Lawn, New Jersey) discs containing 5, 10, or 50 Adams, E., Jeter, D., Cordes, A.W., and Kolis, J.W. (1990). Chemistry of
g of either GSAA or GSAO were then applied to the CAM of individual organometalloid complexes with potential antidotes: structure of an organ-
embryos and incubated for 48 hr at 37C and 3% CO2. The discs were made oarsenic(III) dithiolate ring. Inorg. Chem. 29, 1500–1503.
by desiccation of GSAA or GSAO in 10 l of 0.45% methycellulose on teflon
Ades, E.W., Candal, F.J., Swerlick, R.A., George, V.G., Summers, S., Bosse,rods. The CAMs were observed using a stereomicroscope and scored for
D.C., and Lawley, T.J. (1992). HMEC-1: Establishment of an immortalizedno obvious affect or inhibition of CAM angiogenesis as defined by avascular
human microvascular endothelial cell line. J. Invest. Dermatol. 99, 683–690.zones. On some occasions CAM blood vessels were injected with India ink
and photographed. Barchowsky, A., Roussel, R.R., Klei, L.R., James, P.E., Ganju, N., Smith, K.R.,
and Dudek, E.J. (1999). Low levels of arsenic trioxide stimulate proliferative
Measurement of plasma arsenic signals in primary vascular cells without activating stress effector pathways.
Toxicol. Appl. Pharmacol. 159, 65–75.Female 7- to 9-week-old Balb c mice (University of New South Wales,
Sydney, NSW) were administered 10 mg/kg GSAO in 0.2 ml of PBS con-
Battini, R., Ferrari, S., Kaczmarek, L., Calabretta, B., Chen, S.T., and Baserga,
taining 100 mM glycine by subcutaneous injection in the flank. Blood was R. (1987). Molecular cloning of a cDNA for a human ADP/ATP carrier which
collected by cardiac puncture into 50% acid citrate dextrose at discreet is growth-regulated. J. Biol. Chem. 262, 4355–4359.
time intervals and plasma was prepared. The plasma samples were diluted
Bauer, M.K., Schubert, A., Rocks, O., and Grimm, S. (1999). Adenine nucleo-5-fold with 70% w/w nitric acid to give 1 ml total solution. Small amounts
tide translocase-1, a component of the permeability transition pore, canof solid in the samples were dissolved by incubating at 56C for 2.5 hr,
dominantly induce apoptosis. J. Cell Biol. 147, 1493–1502.before diluting 20-fold with water. The samples were then analyzed for
arsenic using a Elan 6100 Inductively Coupled Plasma Mass Spectrometer Belzacq, A.S., El Hamel, C., Vieira, H.L., Cohen, I., Haouzi, D., Metivier,
(Perkin Elmer Sciex Instruments, Shelton, Connecticut). D., Marchetti, P., Brenner, C., and Kroemer, G. (2001). Adenine nucleotide
translocator mediates the mitochondrial membrane permeabilization in-
Primary tumor growth assays duced by lonidamine, arsenite and CD437. Oncogene 20, 7579–7587.
Female 7- to 9-week-old SCID or C57Bl6/J mice were used (Massachusetts
Bernardi, P., Vassanelli, S., Veronese, P., Colonna, R., Szabo, I., and Zoratti,General Hospital, Boston, Massachusetts). Mice were held in groups of 3
M. (1992). Modulation of the mitochondrial permeability transition pore—to 5 at a 12 hr day and night cycle and were given animal chow and water
effect of protons and divalent cations. J. Biol. Chem. 267, 2934–2939.ad libidum. SCID or C57Bl6/J mice were anesthetized by inhalation of
isoflurane, the dorsal skin shaved and cleaned with ethanol, and a suspen- Boveris, A., Oshino, N., and Chance, B. (1972). The mitochondrial production
sion of 2.5  106 BxPC-3, HT1080, or LLC cells in 0.2 ml of PBS, or saline of hydrogen peroxide. Biochem. J. 128, 617–630.
for LLC cells, was injected subcutaneously in the proximal midline. LLC cells
Carmeliet, P., and Jain, R.K. (2000). Angiogenesis in cancer and other dis-were prepared according to O’Reilly et al. (1997). Tumors were allowed to
eases. Nature 407, 249–257.establish and grow to a size of 0.1 cm3 after which they were randomized
into two groups. Tumor volume was calculated using the relationship, Chen, Y., Cai, J., Murphy, T.J., and Jones, D.P. (2002). Overexpressed
a·b2.0.52, where a is the longest diameter and b the shortest. Animals were human mitochondrial thioredoxin confers resistance to oxidant-induced apo-
treated with either GSAA or GSAO at a dose 10 mg/kg/day in 0.2 ml of PBS ptosis in human osteosarcoma cells. J. Biol. Chem. 277, 33242–33248.
containing 100 mM glycine. The compounds were administered subcutane-
Crompton, M. (1999). The mitochondrial permeability transition pore and itsously at a site distant from the tumor. Tumor volume and animal weight
role in cell death. Biochem. J. 341, 233–249.
were measured every 3 days. The tumors were excised and weighed when
the animals were sacrificed. Crompton, M., Ellinger, H., and Costi, A. (1988). Inhibition by cyclosporin
A of a Ca2-dependent pore in heart mitochondria activated by inorganic
phosphate and oxidative stress. Biochem. J. 255, 357–360.Immunohistochemistry
Excised tumors were fixed in Buffered Formalde-Fresh (Fisher Scientific),
Davis, W., Ronai, Z., and Tew, K.D. (2001). Cellular thiols and reactive oxygen
embedded in paraffin, and 5 m thick sections were cut and placed on species in drug-induced apoptosis. J. Pharmacol. Exp. Ther. 296, 1–6.
glass slides. Sections were stained with haematoxylin and eosin or for CD31,
PCNA (O’Reilly et al., 1997) or fragmented DNA (Gavrieli et al., 1992). Mi- Defilippi, P., Retta, S.F., Olivo, C., Palmieri, M., Venturino, M., Silengo, L.,
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pore. Exp. Cell Res. 249, 413–421.
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